BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 19932148)

  • 1. Neurotensin expression and outcome of malignant pleural mesothelioma.
    Alifano M; Loi M; Camilleri-Broet S; Dupouy S; Régnard JF; Forgez P
    Biochimie; 2010 Feb; 92(2):164-70. PubMed ID: 19932148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurotensin promotes the progression of malignant glioma through NTSR1 and impacts the prognosis of glioma patients.
    Ouyang Q; Gong X; Xiao H; Zhou J; Xu M; Dai Y; Xu L; Feng H; Cui H; Yi L
    Mol Cancer; 2015 Feb; 14():21. PubMed ID: 25644759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.
    Pinton G; Brunelli E; Murer B; Puntoni R; Puntoni M; Fennell DA; Gaudino G; Mutti L; Moro L
    Cancer Res; 2009 Jun; 69(11):4598-604. PubMed ID: 19487281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.
    Hiraki A; Aoe K; Murakami T; Nakamura Y; Yamazaki K; Sueoka N; Taguchi K; Kamei T; Maeda T; Takeyama H; Kishimoto T; Nishimura M; Sugi K
    Oncol Rep; 2005 Aug; 14(2):357-62. PubMed ID: 16012715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel therapeutic target for head and neck squamous cell carcinomas: a role for the neurotensin-neurotensin receptor 1 oncogenic signaling pathway.
    Shimizu S; Tsukada J; Sugimoto T; Kikkawa N; Sasaki K; Chazono H; Hanazawa T; Okamoto Y; Seki N
    Int J Cancer; 2008 Oct; 123(8):1816-23. PubMed ID: 18661521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotensin and neurotensin receptor 1 expression in human myometrium and uterine leiomyomas.
    Rodríguez Y; Almeida TA; Valladares F; Báez D; Montes de Oca F; García C; Dorta I; Hernández M; Reyes R; Bello AR
    Biol Reprod; 2010 Oct; 83(4):641-7. PubMed ID: 20592307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic role of osteopontin expression in malignant pleural mesothelioma.
    Cappia S; Righi L; Mirabelli D; Ceppi P; Bacillo E; Ardissone F; Molinaro L; Scagliotti GV; Papotti M
    Am J Clin Pathol; 2008 Jul; 130(1):58-64. PubMed ID: 18550471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
    Cole GW; Alleva AM; Reddy RM; Maxhimer JB; Zuo J; Schrump DS; Nguyen DM
    J Thorac Cardiovasc Surg; 2005 May; 129(5):1010-7. PubMed ID: 15867774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis.
    Kumar-Singh S; Segers K; Rodeck U; Backhovens H; Bogers J; Weyler J; Van Broeckhoven C; Van Marck E
    J Pathol; 1997 Jan; 181(1):67-74. PubMed ID: 9072005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.
    López-Ríos F; Chuai S; Flores R; Shimizu S; Ohno T; Wakahara K; Illei PB; Hussain S; Krug L; Zakowski MF; Rusch V; Olshen AB; Ladanyi M
    Cancer Res; 2006 Mar; 66(6):2970-9. PubMed ID: 16540645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
    Dupouy S; Doan VK; Wu Z; Mourra N; Liu J; De Wever O; Llorca FP; Cayre A; Kouchkar A; Gompel A; Forgez P
    Oncotarget; 2014 Sep; 5(18):8235-51. PubMed ID: 25249538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
    Borasio P; Berruti A; Billé A; Lausi P; Levra MG; Giardino R; Ardissone F
    Eur J Cardiothorac Surg; 2008 Feb; 33(2):307-13. PubMed ID: 18164622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?
    Balduyck B; Trousse D; Nakas A; Martin-Ucar AE; Edwards J; Waller DA
    Ann Thorac Surg; 2010 Mar; 89(3):907-11. PubMed ID: 20172152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma.
    Edwards JG; Swinson DE; Jones JL; Waller DA; O'Byrne KJ
    Lung Cancer; 2006 Dec; 54(3):399-407. PubMed ID: 17049671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma.
    Kumar-Singh S; Vermeulen PB; Weyler J; Segers K; Weyn B; Van Daele A; Dirix LY; Van Oosterom AT; Van Marck E
    J Pathol; 1997 Jun; 182(2):211-6. PubMed ID: 9274533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MT1-MMP plays an important role in an invasive activity of malignant pleural mesothelioma cell.
    Doi T; Maniwa Y; Tanaka Y; Tane S; Hashimoto S; Ohno Y; Nishio W; Nishimura Y; Ohbayashi C; Okita Y; Hayashi Y; Yoshimura M
    Exp Mol Pathol; 2011 Feb; 90(1):91-6. PubMed ID: 20969861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of in vitro cell motility and invasiveness of human malignant pleural mesothelioma cells through the HIF-1α-MUC1 pathway.
    Goudarzi H; Iizasa H; Furuhashi M; Nakazawa S; Nakane R; Liang S; Hida Y; Yanagihara K; Kubo T; Nakagawa K; Kobayashi M; Irimura T; Hamada J
    Cancer Lett; 2013 Oct; 339(1):82-92. PubMed ID: 23879962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathologic evaluation of malignant pleural mesothelioma.
    Chirieac LR; Corson JM
    Semin Thorac Cardiovasc Surg; 2009; 21(2):121-4. PubMed ID: 19822283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.
    Younes M; Wu Z; Dupouy S; Lupo AM; Mourra N; Takahashi T; Fléjou JF; Trédaniel J; Régnard JF; Damotte D; Alifano M; Forgez P
    Oncotarget; 2014 Sep; 5(18):8252-69. PubMed ID: 25249545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients.
    Bahnassy AA; Zekri AR; Abou-Bakr AA; El-Deftar MM; El-Bastawisy A; Sakr MA; El-Sherif GM; Gaafar RM
    Exp Mol Pathol; 2012 Aug; 93(1):154-61. PubMed ID: 22504106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.